[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  Arvinas, Inc (ARVN) Arvinas, Inc. (ARVN) and Pfizer to present new Vepdegestrant data at ESMO 2025, but the stock faces mixed sentiment due to analyst downgrades and market volatility. ### About Arvinas, Inc Arvinas, Inc. (ARVN) is a biotechnology company focused on developing protein degraders for various diseases, particularly in oncology. Arvinas, Inc uses the ticker $ARVN for trading. Listed in the [Stocks](/list/stocks) and category within the [Healthcare](/list/stocks/healthcare) sectors. ### Insights [#](/topic/$arvn/insights) - Arvinas, Inc (ARVN) trading volume is up XXXXXX% from the previous month. - Arvinas, Inc (ARVN) social dominance is up XXXXX% from the previous week. - Arvinas, Inc (ARVN) galaxy score™ is up XXXXX% from the previous week. - Arvinas, Inc (ARVN) sentiment is up XX% from the previous week. - Arvinas, Inc (ARVN) posts created is up XXXXXX% from the previous week. ### Price: $XXXX [#](/topic/$arvn/close) ---  [Price 24-Hour Time-Series Raw Data](/topic/$arvn/time-series/close.tsv) The current price of $XXXX appears to be influenced by a mix of positive and negative factors. While the company's revenue growth and upcoming catalysts offer support, analyst downgrades and recent price drops suggest caution. The XXXXX% increase over the last XX days indicates some positive momentum, but the negative 7-day performance and 1-year low suggest potential for further volatility. | 24-Hour | 7-Day | 30-Day | | ------- | ----- | ------ | | -XXXX% | XXXX% | XXXX% | **1-Year High**: $XX on 2024-11-11 **1-Year Low**: $XXXX on 2025-05-14 ### AltRank: XXX [#](/topic/$arvn/alt_rank) ---  [AltRank 24-Hour Time-Series Raw Data](/topic/$arvn/time-series/alt_rank.tsv) Arvinas, Inc (ARVN) is currently AltRank #159 based on combined combined social and market metrics **Daily Average**: XXX **1 Week**: XXX -XXX **1 Month**: XXX -XXX **6 Months**: XXX +79 **1 Year**: XXX -XXX **1-Year High**: XXXXX on 2025-09-04 **1-Year Low**: XX on 2025-01-18 ### Galaxy Score: XXXXX [#](/topic/$arvn/galaxy_score) ---  [Galaxy Score 24-Hour Time-Series Raw Data](/topic/$arvn/time-series/galaxy_score.tsv) **Current Value**: XXXXX **Daily Average**: XX **1 Week**: XX +33 **1 Month**: XX -X **6 Months**: XX +4 **1 Year**: XX +24 **1-Year High**: XX on 2025-07-21 **1-Year Low**: XX on 2024-11-26 ### Engagements: XXXXX [#](/topic/$arvn/interactions) ---  [Engagements 24-Hour Time-Series Raw Data](/topic/$arvn/time-series/interactions.tsv) **Current Value**: XXXXX **Daily Average**: XXXXXX **1 Week**: XXXXXX -XX% **1 Month**: XXXXXX -XX% **6 Months**: XXXXXXXXX -XX% **1 Year**: XXXXXXXXX +121% **1-Year High**: XXXXXXX on 2025-02-11 **1-Year Low**: XXX on 2025-10-11 | Social Network | X | Reddit | YouTube | | -------------- | - | ------ | ------- | | Engagements | XXXXX | X | X | ### Mentions: XX [#](/topic/$arvn/posts_active) ---  [Mentions 24-Hour Time-Series Raw Data](/topic/$arvn/time-series/posts_active.tsv) **Current Value**: XX **Daily Average**: XX **1 Month**: XXX -XX% **6 Months**: XXXXX +7.30% **1 Year**: XXXXX +183% **1-Year High**: XXX on 2025-06-29 **1-Year Low**: XX on 2025-10-12 | Social Network | X | Reddit | YouTube | | -------------- | - | ------ | ------- | | Mentions | XX | X | X | ### Creators: XX [#](/topic/$arvn/contributors_active) ---  [Creators 24-Hour Time-Series Raw Data](/topic/$arvn/time-series/contributors_active.tsv) XX unique social accounts have posts mentioning Arvinas, Inc (ARVN) in the last XX hours which is up XXX% from XX in the previous XX hours **Daily Average**: XX **1 Month**: XX -XX% **6 Months**: XXXXX +92% **1 Year**: XXXXX +174% **1-Year High**: XXX on 2025-06-29 **1-Year Low**: X on 2025-10-12 The most influential creators that mention Arvinas, Inc in the last XX hours | Creator | Rank | Followers | Posts | Engagements | | ------- | ---- | --------- | ----- | ----------- | | [@ByMadeleineA](/creator/twitter/ByMadeleineA) | X | XXXXX | X | XXXXX | | [@Banana_Oncology](/creator/twitter/Banana_Oncology) | X | XXXXX | X | XXX | | [@financebully](/creator/twitter/financebully) | X | XXX | X | XXX | | [@stocket_rocket](/creator/twitter/stocket_rocket) | X | XXX | X | XX | | [@doepke_michel](/creator/twitter/doepke_michel) | X | XXXXX | X | XX | | [@BiopharmIQ](/creator/twitter/BiopharmIQ) | X | XXXXXX | X | XX | | [@Insider_WTrade](/creator/twitter/Insider_WTrade) | X | XXXXX | X | XX | | [@BuyTheUgly](/creator/twitter/BuyTheUgly) | X | XX | X | XX | | [@aultfern](/creator/twitter/aultfern) | X | XXX | X | XX | | [@Biobeats99](/creator/twitter/Biobeats99) | XX | XXX | X | XX | [View More](/list/creators/$arvn/100) ### Sentiment: XX% [#](/topic/$arvn/sentiment) ---  [Sentiment 24-Hour Time-Series Raw Data](/topic/$arvn/time-series/sentiment.tsv) **Current Value**: XX% **Daily Average**: XX% **1 Week**: XX% +25% **1 Month**: XX% -X% **6 Months**: XX% +8% **1 Year**: XX% -XX% **1-Year High**: XXX% on 2024-11-08 **1-Year Low**: XX% on 2025-10-03 **Most Supportive Themes** - **Positive Analyst Ratings and Partnerships:** (25%) Mentions of partnerships and positive analyst ratings, such as the one from Bank of America, are seen as supportive. - **Upcoming Catalysts and Data Releases:** (20%) The anticipation surrounding the ASCO presentation and regulatory filings for ARV-471 is a supportive theme. **Most Critical Themes** - **Analyst Downgrades:** (15%) Downgrades from Truist and BMO are viewed as critical. - **Market Volatility:** (10%) The stock's price fluctuations and negative 7-day performance are critical. Network engagement breakdown: | Network | Positive | % | Neutral | % | Negative | % | | ------- | -------- | - | ------- | - | -------- | - | | X | XXXXX | XX% | XXXXX | XX% | XXX | XX% | | Reddit | X | X% | X | X% | X | X% | | YouTube | X | X% | X | X% | X | X% | | | | | | | | | | Total | XXXXX | XX% | XXXXX | XX% | XXX | XX% | ### Social Dominance: XXXXXXX% [#](/topic/$arvn/social_dominance) ---  [Social Dominance 24-Hour Time-Series Raw Data](/topic/$arvn/time-series/social_dominance.tsv) **Current Value**: XXXXXXX% **Daily Average**: XXXXX% **1 Week**: XXXX% +0.0099% **1 Month**: XXXXXX% +0.0011% **6 Months**: XXXXXX% -XXXXX% **1 Year**: XXXXXX% -XXXXXXXXXXXXXXXXXXXXX% **1-Year High**: XXXXX% on 2025-03-14 **1-Year Low**: XXXXXX% on 2025-10-12 ### Market Dominance: XXXXXXXXXXXXXXXXXXXXX% [#](/topic/$arvn/market_dominance) ---  [Market Dominance 24-Hour Time-Series Raw Data](/topic/$arvn/time-series/market_dominance.tsv) **Current Value**: XXXXXXXXXXXXXXXXXXXXX% **Daily Average**: X% **1-Year High**: XXXXXXX% on 2024-11-22 **1-Year Low**: XXXXXXX% on 2025-08-07 ### Market Cap: $XXXXXXXXXXX [#](/topic/$arvn/market_cap) ---  [Market Cap 24-Hour Time-Series Raw Data](/topic/$arvn/time-series/market_cap.tsv) **Current Value**: $XXXXXXXXXXX **Daily Average**: $XXXXXXXXXXX **1 Week**: $XXXXXXXXXXX +$3% **1 Month**: $XXXXXXXXXXX +$23% **6 Months**: $XXXXXXXXXXX +$9.40% **1 Year**: $XXXXXXXXXXX -$62% **1-Year High**: $XXXXXXXXXXXXX on 2024-11-11 **1-Year Low**: $XXXXXXXXXXX on 2025-04-08 **Top assets mentioned** In the posts about Arvinas, Inc in the last XX hours [Pfizer, Inc. (PFE)](/topic/$pfe) [Dave Inc. Class A Common Stock (DAVE)](/topic/$dave) [Moonft (MTC)](/topic/$mtc) [CRISPR Therapeutics AG (CRSP)](/topic/$crsp) [Eli Lilly and Company (LLY)](/topic/eli-lilly) [Kymera Therapeutics, Inc. Common Stock (KYMR)](/topic/$kymr) [Elanco Animal Health Incorporated Common Stock (ELAN)](/topic/$elan) [Apellis Pharmaceuticals, Inc. Common Stock (APLS)](/topic/$apls) [Eli Lilly and Company (LLY)](/topic/$lly) **Top topics mentioned** In the posts about Arvinas, Inc in the last XX hours [stocks healthcare](/topic/stocks-healthcare), [coins made in usa](/topic/coins-made-in-usa), [$pfe](/topic/$pfe), [$gsun](/topic/$gsun), [stocks consumer cyclical](/topic/stocks-consumer-cyclical), [discord](/topic/discord), [$dave](/topic/$dave), [stocks technology](/topic/stocks-technology), [$mtc](/topic/$mtc), [coins defi](/topic/coins-defi), [investment](/topic/investment), [$cmnd](/topic/$cmnd), [$crsp](/topic/$crsp), [eli lilly](/topic/eli-lilly), [stocks](/topic/stocks), [stocks financial services](/topic/stocks-financial-services), [breast cancer](/topic/breast-cancer), [$kymr](/topic/$kymr), [$elan](/topic/$elan), [stocks industrials](/topic/stocks-industrials), [$apls](/topic/$apls), [$lly](/topic/$lly), [$imab](/topic/$imab), [$tlsa](/topic/$tlsa), [$amph](/topic/$amph), [$absi](/topic/$absi), [coins base ecosystem](/topic/coins-base-ecosystem), [$spy](/topic/$spy), [momentum](/topic/momentum), [$snes](/topic/$snes), [$txmd](/topic/$txmd), [$rhhby](/topic/$rhhby), [money](/topic/money), [coins bsc](/topic/coins-bsc), [coins layer 1](/topic/coins-layer-1), [$bce](/topic/$bce), [$logi](/topic/$logi), [$mgy](/topic/$mgy), [$axta](/topic/$axta), [$cx](/topic/$cx), [coins dao](/topic/coins-dao), [$apld](/topic/$apld), [$uamy](/topic/$uamy), [$pepg](/topic/$pepg), [$uuu](/topic/$uuu), [coins](/topic/coins), [$spwh](/topic/$spwh), [$rhhy](/topic/$rhhy), [$kmda](/topic/$kmda), [$ptn](/topic/$ptn), [$abnb](/topic/$abnb), [$apps](/topic/$apps), [$elog](/topic/$elog), [amphenol](/topic/amphenol), [$nvda](/topic/$nvda), [$run](/topic/$run), [thomson reuters](/topic/thomson-reuters), [$100m](/topic/$100m), [100m](/topic/100m), [hims hers](/topic/hims-hers), [stocks consumer defensive](/topic/stocks-consumer-defensive), [$hims](/topic/$hims), [lucid group inc](/topic/lucid-group-inc), [insider](/topic/insider), [$admq](/topic/$admq), [$lrcx](/topic/$lrcx), [$pali](/topic/$pali), [$120m](/topic/$120m), [primary market](/topic/primary-market), [$acog](/topic/$acog), [rocket companies inc](/topic/rocket-companies-inc), [$asts](/topic/$asts), [$rkt](/topic/$rkt), [$stocks](/topic/$stocks), [8k](/topic/8k), [has been](/topic/has-been), [united states](/topic/united-states), [rating agency](/topic/rating-agency), [$atge](/topic/$atge), [$asm](/topic/$asm), [coins nft](/topic/coins-nft), [$700m](/topic/$700m), [cuts](/topic/cuts), [$crml](/topic/$crml), [$ibkr](/topic/$ibkr), [$ciit](/topic/$ciit), [frost](/topic/frost), [$7b](/topic/$7b), [market cap](/topic/market-cap), [$12m](/topic/$12m), [$441k](/topic/$441k), [$423k](/topic/$423k), [$425k](/topic/$425k), [poa](/topic/poa), [up the](/topic/up-the), [os](/topic/os), [$celc](/topic/$celc), [$olma](/topic/$olma), [$35m](/topic/$35m), [drops](/topic/drops) ### Top Social Posts [#](/topic/$arvn/posts) --- Top posts by engagements in the last XX hours *Showing only X posts for non-authenticated requests. Use your API key in requests for full results.* "@seedy19tron @Andre_AGTC @WallStSai don't short $celc brian sullivan. ;) roche data is bs - mutESR1 population is likely driving the benefit in the itt group. after $arvn data i don't see any serd winning in itt including $olma unless they fudge data by more favorable pt population" [X Link](https://x.com/financebully/status/1979577507788841389) [@financebully](/creator/x/financebully) 2025-10-18T15:57Z XXX followers, XXX engagements "Roche pill delays tumor progression in closely watched breast cancer study @ByJonGardner $RHHBY $LLY $ARVN #ESMO25" [X Link](https://x.com/BentheFidler/status/1979537545487958161) [@BentheFidler](/creator/x/BentheFidler) 2025-10-18T13:18Z 8329 followers, XXX engagements "@ByMadeleineA I assume theyll want contribution of components Seems short sighted that $pfe gave up given the others are clearly fudging their numbers with more favorable patient population. $arvn" [X Link](https://x.com/financebully/status/1979478632423645187) [@financebully](/creator/x/financebully) 2025-10-18T09:24Z XXX followers, XXX engagements "Well these are the most promising signs I think we've seen in non-ESR1m pts with a SERD. And $RHHBY has been clever by enrolling XX% of pts in Evera with ESR1m. Now over to the FDA #ESMO25 $LLY $PFE $ARVN" [X Link](https://x.com/ByMadeleineA/status/1979466325064880363) [@ByMadeleineA](/creator/x/ByMadeleineA) 2025-10-18T08:35Z 8066 followers, 1459 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Arvinas, Inc. (ARVN) and Pfizer to present new Vepdegestrant data at ESMO 2025, but the stock faces mixed sentiment due to analyst downgrades and market volatility.
Arvinas, Inc. (ARVN) is a biotechnology company focused on developing protein degraders for various diseases, particularly in oncology.
Arvinas, Inc uses the ticker $ARVN for trading. Listed in the Stocks and category within the Healthcare sectors.
Price 24-Hour Time-Series Raw Data
The current price of $XXXX appears to be influenced by a mix of positive and negative factors. While the company's revenue growth and upcoming catalysts offer support, analyst downgrades and recent price drops suggest caution. The XXXXX% increase over the last XX days indicates some positive momentum, but the negative 7-day performance and 1-year low suggest potential for further volatility.
24-Hour | 7-Day | 30-Day |
---|---|---|
-XXXX% | XXXX% | XXXX% |
1-Year High: $XX on 2024-11-11
1-Year Low: $XXXX on 2025-05-14
AltRank 24-Hour Time-Series Raw Data
Arvinas, Inc (ARVN) is currently AltRank #159 based on combined combined social and market metrics
Daily Average: XXX
1 Week: XXX -XXX
1 Month: XXX -XXX
6 Months: XXX +79
1 Year: XXX -XXX
1-Year High: XXXXX on 2025-09-04
1-Year Low: XX on 2025-01-18
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: XXXXX
Daily Average: XX
1 Week: XX +33
1 Month: XX -X
6 Months: XX +4
1 Year: XX +24
1-Year High: XX on 2025-07-21
1-Year Low: XX on 2024-11-26
Engagements 24-Hour Time-Series Raw Data
Current Value: XXXXX
Daily Average: XXXXXX
1 Week: XXXXXX -XX%
1 Month: XXXXXX -XX%
6 Months: XXXXXXXXX -XX%
1 Year: XXXXXXXXX +121%
1-Year High: XXXXXXX on 2025-02-11
1-Year Low: XXX on 2025-10-11
Social Network | X | YouTube | |
---|---|---|---|
Engagements | XXXXX | X | X |
Mentions 24-Hour Time-Series Raw Data
Current Value: XX
Daily Average: XX
1 Month: XXX -XX%
6 Months: XXXXX +7.30%
1 Year: XXXXX +183%
1-Year High: XXX on 2025-06-29
1-Year Low: XX on 2025-10-12
Social Network | X | YouTube | |
---|---|---|---|
Mentions | XX | X | X |
Creators 24-Hour Time-Series Raw Data
XX unique social accounts have posts mentioning Arvinas, Inc (ARVN) in the last XX hours which is up XXX% from XX in the previous XX hours
Daily Average: XX
1 Month: XX -XX%
6 Months: XXXXX +92%
1 Year: XXXXX +174%
1-Year High: XXX on 2025-06-29
1-Year Low: X on 2025-10-12
The most influential creators that mention Arvinas, Inc in the last XX hours
Creator | Rank | Followers | Posts | Engagements |
---|---|---|---|---|
@ByMadeleineA | X | XXXXX | X | XXXXX |
@Banana_Oncology | X | XXXXX | X | XXX |
@financebully | X | XXX | X | XXX |
@stocket_rocket | X | XXX | X | XX |
@doepke_michel | X | XXXXX | X | XX |
@BiopharmIQ | X | XXXXXX | X | XX |
@Insider_WTrade | X | XXXXX | X | XX |
@BuyTheUgly | X | XX | X | XX |
@aultfern | X | XXX | X | XX |
@Biobeats99 | XX | XXX | X | XX |
Sentiment 24-Hour Time-Series Raw Data
Current Value: XX%
Daily Average: XX%
1 Week: XX% +25%
1 Month: XX% -X%
6 Months: XX% +8%
1 Year: XX% -XX%
1-Year High: XXX% on 2024-11-08
1-Year Low: XX% on 2025-10-03
Most Supportive Themes
Most Critical Themes
Network engagement breakdown:
Network | Positive | % | Neutral | % | Negative | % |
---|---|---|---|---|---|---|
X | XXXXX | XX% | XXXXX | XX% | XXX | XX% |
X | X% | X | X% | X | X% | |
YouTube | X | X% | X | X% | X | X% |
Total | XXXXX | XX% | XXXXX | XX% | XXX | XX% |
Social Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXXXX%
Daily Average: XXXXX%
1 Week: XXXX% +0.0099%
1 Month: XXXXXX% +0.0011%
6 Months: XXXXXX% -XXXXX%
1 Year: XXXXXX% -XXXXXXXXXXXXXXXXXXXXX%
1-Year High: XXXXX% on 2025-03-14
1-Year Low: XXXXXX% on 2025-10-12
Market Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXXXXXXXXXXXXXXXXXX%
Daily Average: X%
1-Year High: XXXXXXX% on 2024-11-22
1-Year Low: XXXXXXX% on 2025-08-07
Market Cap 24-Hour Time-Series Raw Data
Current Value: $XXXXXXXXXXX
Daily Average: $XXXXXXXXXXX
1 Week: $XXXXXXXXXXX +$3%
1 Month: $XXXXXXXXXXX +$23%
6 Months: $XXXXXXXXXXX +$9.40%
1 Year: $XXXXXXXXXXX -$62%
1-Year High: $XXXXXXXXXXXXX on 2024-11-11
1-Year Low: $XXXXXXXXXXX on 2025-04-08
Top assets mentioned In the posts about Arvinas, Inc in the last XX hours
Pfizer, Inc. (PFE) Dave Inc. Class A Common Stock (DAVE) Moonft (MTC) CRISPR Therapeutics AG (CRSP) Eli Lilly and Company (LLY) Kymera Therapeutics, Inc. Common Stock (KYMR) Elanco Animal Health Incorporated Common Stock (ELAN) Apellis Pharmaceuticals, Inc. Common Stock (APLS) Eli Lilly and Company (LLY)
Top topics mentioned In the posts about Arvinas, Inc in the last XX hours
stocks healthcare, coins made in usa, $pfe, $gsun, stocks consumer cyclical, discord, $dave, stocks technology, $mtc, coins defi, investment, $cmnd, $crsp, eli lilly, stocks, stocks financial services, breast cancer, $kymr, $elan, stocks industrials, $apls, $lly, $imab, $tlsa, $amph, $absi, coins base ecosystem, $spy, momentum, $snes, $txmd, $rhhby, money, coins bsc, coins layer 1, $bce, $logi, $mgy, $axta, $cx, coins dao, $apld, $uamy, $pepg, $uuu, coins, $spwh, $rhhy, $kmda, $ptn, $abnb, $apps, $elog, amphenol, $nvda, $run, thomson reuters, $100m, 100m, hims hers, stocks consumer defensive, $hims, lucid group inc, insider, $admq, $lrcx, $pali, $120m, primary market, $acog, rocket companies inc, $asts, $rkt, $stocks, 8k, has been, united states, rating agency, $atge, $asm, coins nft, $700m, cuts, $crml, $ibkr, $ciit, frost, $7b, market cap, $12m, $441k, $423k, $425k, poa, up the, os, $celc, $olma, $35m, drops
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"@seedy19tron @Andre_AGTC @WallStSai don't short $celc brian sullivan. ;) roche data is bs - mutESR1 population is likely driving the benefit in the itt group. after $arvn data i don't see any serd winning in itt including $olma unless they fudge data by more favorable pt population"
X Link @financebully 2025-10-18T15:57Z XXX followers, XXX engagements
"Roche pill delays tumor progression in closely watched breast cancer study @ByJonGardner $RHHBY $LLY $ARVN #ESMO25"
X Link @BentheFidler 2025-10-18T13:18Z 8329 followers, XXX engagements
"@ByMadeleineA I assume theyll want contribution of components Seems short sighted that $pfe gave up given the others are clearly fudging their numbers with more favorable patient population. $arvn"
X Link @financebully 2025-10-18T09:24Z XXX followers, XXX engagements
"Well these are the most promising signs I think we've seen in non-ESR1m pts with a SERD. And $RHHBY has been clever by enrolling XX% of pts in Evera with ESR1m. Now over to the FDA #ESMO25 $LLY $PFE $ARVN"
X Link @ByMadeleineA 2025-10-18T08:35Z 8066 followers, 1459 engagements
/topic/$arvn